

Maria Stefania Sciallero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3029768/publications.pdf>

Version: 2024-02-01

49
papers

1,743
citations

361413

20
h-index

265206

42
g-index

51
all docs

51
docs citations

51
times ranked

2191
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 36-45.	3.9	25
2	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4709.	4.1	13
3	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 615-636.	5.7	21
4	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020, 5, e001001.	4.5	11
5	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. <i>Cancers</i> , 2020, 12, 1007.	3.7	19
6	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer—In Reply. <i>JAMA Oncology</i> , 2019, 5, 1512.	7.1	1
7	Maintenance Olaparib for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1491-1493.	27.0	9
8	HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 605.	7.1	32
9	Streamlining universal screening for lynch syndrome (LS): Towards improved yield of genetic counseling (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 503-503.	1.6	2
10	Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer. <i>Annals of Oncology</i> , 2017, 28, 2620-2621.	1.2	2
11	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147.	4.5	36
12	Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development. <i>PLoS ONE</i> , 2017, 12, e0189123.	2.5	2
13	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1265-1269.	3.3	4
14	Assessing Generalizability of the Findings of Sigmoidoscopy Screening Trials: The Case of SCORE Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, 385.	6.3	4
15	Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement. <i>Public Health Genomics</i> , 2015, 18, 225-232.	1.0	23
16	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1041-1052.	4.2	55
17	<i>CDKN2A</i> is the main susceptibility gene in Italian pancreatic cancer families. <i>Journal of Medical Genetics</i> , 2012, 49, 164-170.	3.2	64
18	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. <i>Familial Cancer</i> , 2012, 11, 41-47.	1.9	32

#	ARTICLE	IF	CITATIONS
19	Once-Only Sigmoidoscopy Screening for Colorectal Cancer: Incidence and Mortality Follow-up of the Italian Randomized Controlled Trial (SCORE). <i>Gastroenterology</i> , 2011, 140, S-15.	1.3	1
20	Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial-SCORE. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1310-1322.	6.3	539
21	Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. <i>Annals of Oncology</i> , 2011, 22, 973-978.	1.2	15
22	Informed Decisions Regarding Microsatellite Instability Testing: Need for an Intention-to-Screen Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, e537-e537.	1.6	3
23	Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. <i>Familial Cancer</i> , 2009, 8, 547-553.	1.9	34
24	Prostate cancer screening with PSA: new data, old debate. <i>Oncology Reviews</i> , 2009, 3, 133-135.	1.8	0
25	First-line single-agent cetuximab in patients with advanced colorectal cancer. <i>Annals of Oncology</i> , 2008, 19, 711-716.	1.2	40
26	History of negative colorectal endoscopy and risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy. <i>International Journal of Colorectal Disease</i> , 2006, 21, 105-113.	2.2	7
27	Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months vs why not 3 months?. <i>Annals of Oncology</i> , 2005, 16, 521-522.	1.2	2
28	Predicting Proximal Advanced Neoplasms at Screening Sigmoidoscopy. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1331-1340.	1.3	17
29	Predictive value of rectal bleeding for distal colonic neoplastic lesions in a screened population. <i>European Journal of Cancer</i> , 2004, 40, 245-252.	2.8	20
30	Interobserver agreement in the histologic diagnosis of colorectal polyps the experience of the multicenter adenoma colorectal study (SMAC). <i>Journal of Clinical Epidemiology</i> , 2003, 56, 209-214.	5.0	83
31	Prevalence of the E1317Q Variant of the APC Gene in Italian Patients with Colorectal Adenomas. <i>Genetic Testing and Molecular Biomarkers</i> , 2002, 6, 313-317.	1.7	16
32	Baseline Findings of the Italian Multicenter Randomized Controlled Trial of "Once-Only Sigmoidoscopy"-SCORE. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1763-1772.	6.3	206
33	Absolute risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy and history of negative colorectal endoscopy (SCORE trial-Italy). <i>Gastroenterology</i> , 2000, 118, A441.	1.3	0
34	Gastroesophageal reflux disease: relationship between clinical and histological features. GOSPE. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2412-2418.	2.3	14
35	Do patients with rectosigmoid adenomas 5 mm or less in diameter need total colonoscopy?. <i>Gastrointestinal Endoscopy</i> , 1999, 50, 314-321.	1.0	20
36	Novel germline APC variants in patients with multiple adenomas. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 257-267.	2.8	33

#	ARTICLE	IF	CITATIONS
37	Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 881-885.	1.6	50
38	Cytokeratin immunostaining reveals micrometastasis in negative hematoxylin-eosin lymph nodes of resected stage I-II (pT2-pT3) colorectal cancer. <i>Journal of Chemotherapy</i> , 1997, 9, 119-120.	1.5	6
39	Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. <i>Gastrointestinal Endoscopy</i> , 1997, 46, 124-130.	1.0	42
40	Lack of prognostic value of flow cytometric DNA content analysis in colorectal adenocarcinomas. <i>European Journal of Cancer</i> , 1994, 30, 569.	2.8	3
41	DNA aneuploidy is an independent factor of poor prognosis in pancreatic and peripancreatic cancer. <i>International Journal of Gastrointestinal Cancer</i> , 1993, 14, 21-28.	0.4	16
42	DNA Content Analysis of Barrett's Esophagus by Flow Cytometry. <i>Endoscopy</i> , 1993, 25, 648-651.	1.8	14
43	Socioeconomic characteristics, life style, diabetes, family history of cancer and risk of pancreatic cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 1993, 5, 367-372.	1.6	3
44	Flow cytometric DNA index in the prognosis of colorectal cancer. <i>Cancer</i> , 1991, 67, 1921-1927.	4.1	77
45	DNA Flow Cytometry of Endoscopically Examined Colorectal Adenocarcinomas. <i>Pathology Research and Practice</i> , 1989, 185, 589-593.	2.3	11
46	Flow cytometric DNA ploidy in colorectal adenomas and family history of colorectal cancer. <i>Cancer</i> , 1988, 61, 114-120.	4.1	40
47	DNA flow cytometry of endoscopically examined colorectal adenomas and adenocarcinomas. <i>Cytometry</i> , 1988, 9, 238-244.	1.8	54
48	The Clinical Significance of Gastric Epithelial Dysplasia. <i>Endoscopy</i> , 1986, 18, 174-176.	1.8	20
49	In vitro effects of ranitidine on human lymphocyte functions. <i>International Journal of Immunopharmacology</i> , 1985, 7, 369.	1.1	2